Blockchain Registration Transaction Record

Clene's CNM-Au8 Shows Promising Brain Energy Improvements in MS Trial

Clene's CNM-Au8 shows significant brain energy improvements in MS trial, targeting metabolic dysfunction. Promising results presented at European MS congress suggest new treatment approach.

This development represents a significant advancement in multiple sclerosis treatment by targeting the underlying metabolic dysfunction rather than just immune system modulation. For the approximately 2.8 million people worldwide living with MS, CNM-Au8's mechanism of improving brain energy metabolism addresses a fundamental aspect of disease progression that current treatments don't adequately cover. The demonstrated improvements in NAD+/NADH ratios suggest potential for slowing disability progression and preserving neurological function, which could meaningfully impact patients' quality of life and long-term outcomes. As neurodegenerative diseases increasingly burden healthcare systems, therapies that address root causes rather than symptoms represent the future of neurological care.